Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

0
Player Avatar usubanas (99.71) Submitted: 3/22/2011 4:44:08 PM : Outperform Start Price: $5.17 SNTA Score: -20.45

Ohad Hammer convinced me.

Featured Broker Partners


Advertisement